Anika Historical Income Statement

ANIK Stock

USD 17.20 0.23 1.36%

Historical analysis of Anika Therapeutics income statement accounts such as Interest Expense of 1.3 M, Selling General Administrative of 103.5 M or Total Revenue of 175 M can show how well Anika Therapeutics performed in making a profits. Evaluating Anika Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Anika Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Anika Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Anika Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

About Anika Income Statement Analysis

Anika Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Anika Therapeutics shareholders. The income statement also shows Anika investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Anika Therapeutics Income Statement Chart

At this time, Anika Therapeutics' Cost Of Revenue is quite stable compared to the past year. Total Operating Expenses is expected to rise to about 201 M this year, although the value of EBIT is projected to rise to (11.1 M).

Selling General Administrative Total Revenue Gross Profit Other Operating Expenses

Total Revenue

Total revenue comprises all receipts Anika Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Anika Therapeutics minus its cost of goods sold. It is profit before Anika Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Anika Therapeutics. It is also known as Anika Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Anika Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Anika Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.At this time, Anika Therapeutics' Cost Of Revenue is quite stable compared to the past year. Total Operating Expenses is expected to rise to about 201 M this year, although the value of EBIT is projected to rise to (11.1 M).

	2021	2022	2023	2024 (projected)
Gross Profit	82.9M	93.6M	103.1M	108.2M
Total Revenue	147.8M	156.2M	166.7M	175.0M

Gross Profit Total Revenue

Anika Therapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Net Income	Income Tax Expense	Research Development	Total Other Income Expense Net	Net Income From Continuing Ops	Non Recurring	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		-0.04	0.9	0.86	0.63	0.91	-0.76	-0.75	-0.65	0.99	0.86	-0.73	-0.71	-0.7	0.91	0.33	-0.8	0.55	-0.94	0.87	0.23	0.97	-0.49
Interest Expense	-0.04		0.06	0.07	0.11	0.03	0.0	0.08	0.08	0.0	0.05	0.0	0.0	-0.03	0.03	0.08	0.05	-0.01	-0.03	0.25	0.5	-0.07	-0.04
Selling General Administrative	0.9	0.06		0.86	0.7	0.98	-0.87	-0.69	-0.61	0.92	0.98	-0.86	-0.86	-0.69	0.94	0.59	-0.83	0.59	-0.92	0.89	0.56	0.88	-0.72
Total Revenue	0.86	0.07	0.86		0.94	0.88	-0.55	-0.35	-0.22	0.89	0.85	-0.52	-0.54	-0.33	0.93	0.52	-0.5	0.81	-0.8	0.81	0.44	0.77	-0.54
Gross Profit	0.63	0.11	0.7	0.94		0.71	-0.31	-0.03	0.1	0.67	0.7	-0.28	-0.33	-0.02	0.79	0.59	-0.21	0.88	-0.59	0.65	0.51	0.53	-0.48
Other Operating Expenses	0.91	0.03	0.98	0.88	0.71		-0.88	-0.67	-0.58	0.93	0.99	-0.86	-0.87	-0.66	0.95	0.57	-0.81	0.59	-0.9	0.87	0.54	0.88	-0.76
Operating Income	-0.76	0.0	-0.87	-0.55	-0.31	-0.88		0.83	0.8	-0.76	-0.9	0.99	0.98	0.84	-0.75	-0.46	0.92	-0.24	0.79	-0.73	-0.49	-0.79	0.77
Ebit	-0.75	0.08	-0.69	-0.35	-0.03	-0.67	0.83		0.99	-0.72	-0.63	0.84	0.76	0.98	-0.6	-0.14	0.94	-0.04	0.79	-0.68	-0.1	-0.82	0.36
Ebitda	-0.65	0.08	-0.61	-0.22	0.1	-0.58	0.8	0.99		-0.62	-0.55	0.81	0.73	0.98	-0.5	-0.1	0.91	0.07	0.71	-0.59	-0.07	-0.74	0.32
Cost Of Revenue	0.99	0.0	0.92	0.89	0.67	0.93	-0.76	-0.72	-0.62		0.88	-0.74	-0.72	-0.68	0.92	0.33	-0.79	0.56	-0.93	0.86	0.27	0.94	-0.53
Total Operating Expenses	0.86	0.05	0.98	0.85	0.7	0.99	-0.9	-0.63	-0.55	0.88		-0.88	-0.89	-0.63	0.93	0.63	-0.79	0.59	-0.86	0.85	0.61	0.83	-0.82
Income Before Tax	-0.73	0.0	-0.86	-0.52	-0.28	-0.86	0.99	0.84	0.81	-0.74	-0.88		0.99	0.83	-0.72	-0.45	0.95	-0.22	0.78	-0.71	-0.49	-0.77	0.77
Net Income	-0.71	0.0	-0.86	-0.54	-0.33	-0.87	0.98	0.76	0.73	-0.72	-0.89	0.99		0.75	-0.72	-0.48	0.91	-0.25	0.74	-0.68	-0.52	-0.73	0.82
Income Tax Expense	-0.7	-0.03	-0.69	-0.33	-0.02	-0.66	0.84	0.98	0.98	-0.68	-0.63	0.83	0.75		-0.61	-0.23	0.9	-0.05	0.79	-0.71	-0.23	-0.78	0.38
Research Development	0.91	0.03	0.94	0.93	0.79	0.95	-0.75	-0.6	-0.5	0.92	0.93	-0.72	-0.72	-0.61		0.6	-0.69	0.73	-0.93	0.92	0.5	0.87	-0.62
Total Other Income Expense Net	0.33	0.08	0.59	0.52	0.59	0.57	-0.46	-0.14	-0.1	0.33	0.63	-0.45	-0.48	-0.23	0.6		-0.26	0.58	-0.48	0.62	0.82	0.33	-0.6
Net Income From Continuing Ops	-0.8	0.05	-0.83	-0.5	-0.21	-0.81	0.92	0.94	0.91	-0.79	-0.79	0.95	0.91	0.9	-0.69	-0.26		-0.16	0.82	-0.71	-0.27	-0.83	0.58
Non Recurring	0.55	-0.01	0.59	0.81	0.88	0.59	-0.24	-0.04	0.07	0.56	0.59	-0.22	-0.25	-0.05	0.73	0.58	-0.16		-0.59	0.64	0.4	0.51	-0.35
Tax Provision	-0.94	-0.03	-0.92	-0.8	-0.59	-0.9	0.79	0.79	0.71	-0.93	-0.86	0.78	0.74	0.79	-0.93	-0.48	0.82	-0.59		-0.95	-0.39	-0.95	0.49
Interest Income	0.87	0.25	0.89	0.81	0.65	0.87	-0.73	-0.68	-0.59	0.86	0.85	-0.71	-0.68	-0.71	0.92	0.62	-0.71	0.64	-0.95		0.56	0.86	-0.52
Net Interest Income	0.23	0.5	0.56	0.44	0.51	0.54	-0.49	-0.1	-0.07	0.27	0.61	-0.49	-0.52	-0.23	0.5	0.82	-0.27	0.4	-0.39	0.56		0.2	-0.68
Reconciled Depreciation	0.97	-0.07	0.88	0.77	0.53	0.88	-0.79	-0.82	-0.74	0.94	0.83	-0.77	-0.73	-0.78	0.87	0.33	-0.83	0.51	-0.95	0.86	0.2		-0.41
Extraordinary Items	-0.49	-0.04	-0.72	-0.54	-0.48	-0.76	0.77	0.36	0.32	-0.53	-0.82	0.77	0.82	0.38	-0.62	-0.6	0.58	-0.35	0.49	-0.52	-0.68	-0.41

Click cells to compare fundamentals

Anika Therapeutics Account Relationship Matchups

Anika Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	6.0M	15.0M	16.0M	14.5M	14.2M	14.9M
Interest Expense	7.9M	302K	188K	654K	2.3M	1.3M
Selling General Administrative	35.0M	60.1M	53.0M	84.8M	98.6M	103.5M
Total Revenue	114.6M	130.5M	147.8M	156.2M	166.7M	175.0M
Gross Profit	85.9M	69.0M	82.9M	93.6M	103.1M	108.2M
Other Operating Expenses	80.4M	144.9M	166.3M	175.6M	254.3M	267.0M
Operating Income	34.2M	(14.5M)	(18.5M)	(19.4M)	(87.6M)	(83.3M)
Ebit	34.2M	(27.8M)	(13.4M)	(19.4M)	(11.7M)	(11.1M)
Ebitda	40.2M	(12.8M)	2.6M	(4.9M)	2.5M	2.4M
Cost Of Revenue	28.7M	61.4M	64.9M	62.7M	63.6M	66.8M
Total Operating Expenses	51.6M	83.5M	101.4M	113.0M	191.5M	201.0M
Income Before Tax	36.1M	(28.6M)	2.4M	(18.7M)	(85.3M)	(81.1M)
Net Income	27.2M	(24.0M)	4.1M	(14.9M)	(82.7M)	(78.5M)
Income Tax Expense	8.9M	(4.6M)	(1.7M)	(3.9M)	(2.7M)	(2.5M)
Research Development	16.7M	23.4M	27.3M	28.2M	32.7M	34.3M
Total Other Income Expense Net	1.9M	(302K)	(188K)	654K	2.3M	2.4M
Net Income Applicable To Common Shares	27.2M	(24.0M)	4.1M	(14.9M)	(17.1M)	(16.2M)
Net Income From Continuing Ops	27.2M	(24.0M)	4.1M	(14.9M)	(24.6M)	(23.3M)
Tax Provision	8.9M	(4.6M)	(1.7M)	(3.9M)	(3.9M)	(3.7M)
Net Interest Income	1.9M	(302K)	(188K)	654K	2.0M	2.1M
Reconciled Depreciation	6.0M	13.5M	14.3M	14.5M	14.3M	11.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:

How To Invest In Anika

Details

Is Anika Stock a good investment?

Details

What is Anika Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.51)

Earnings Share

(6.73)

Revenue Per Share

11.139

Quarterly Revenue Growth

(0.07)

Return On Assets

(0.04)

The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Anika Historical Income Statement

About Anika Income Statement Analysis

Anika Therapeutics Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Anika Therapeutics income statement Correlations

Anika Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Anika Therapeutics income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 0.99	Depreciation And Amortization
Total Operating Expenses	+ 0.99	Other Operating Expenses
Income Before Tax	+ 0.99	Operating Income
Ebitda	+ 0.99	Ebit
Net Income	+ 0.99	Income Before Tax
Other Operating Expenses	+ 0.98	Selling General Administrative

Reconciled Depreciation	- 0.95	Tax Provision
Interest Income	- 0.95	Tax Provision
Tax Provision	- 0.94	Depreciation And Amortization
Tax Provision	- 0.93	Research Development
Tax Provision	- 0.93	Cost Of Revenue
Tax Provision	- 0.92	Selling General Administrative